TargetBeta
IL17F
interleukin 17F · also IL-17F, ML-1, ML1 · Interleukins
2 programs in company-led studies act on IL17F, from 2 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| bimekizumabrule | UCB | phase 3 | 437 running | IL17A | ChEMBL |
| sonelokimabrule | MoonLake Immunotherapeutics | phase 3 | 124 running | IL17A | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Arthritis, Psoriatic, 2 programs
- Hidradenitis Suppurativa, 2 programs
- Psoriasis, 2 programs
- Axial Spondyloarthritis, 1 program
- Spondylitis, Ankylosing, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 21, 2026bimekizumab · UCB · phase 3 · NCT06921850
- Jan 4, 2027sonelokimab · MoonLake Immunotherapeutics · phase 3 · NCT06641089
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.